Categories
- Active Surveillance
- Announcements
- Ask Dr. Barken
- Biomarker
- Biopsy
- Bone Metastases
- Brachytherapy
- Cancer Stem Cells
- Castration Resistant Prostate Cancer
- CETC
- Checklist
- Choline 11 PET Scan
- Clinical Trials
- Coaching
- Color Doppler Trans-Rectal Ultrasound
- Cryo Immunotherapy
- Cryoablation
- CTC
- Decision Making
- Diagnosis
- Exosome
- Ferumoxytol
- Focal Therapy
- Genome
- HIFU
- High Intensity Foucused Ultrasound
- Hormonal Blockade
- Hormone Refractory Disease
- Imaging
- Immune Therapy
- Intermittent Hormonal Blockade
- Journal Club
- Laser
- LIfe Style
- Liquid Biopsy
- Lymph Nodes
- Markers
- Metastatic Disease
- Metastatic Prostate Cancer Disease
- MRI
- MRI Guided Focal
- Multi Parameteric MRI
- Nutrition
- PCREF Support Group Meeting
- PET scans
- Photodynamic Therapy
- Prevention
- Prognosis
- Prostate Cancer
- PSA
- Radiation Therapy
- Radiation treatment
- Radical Prostatectomy
- Sequential Hormonal Blockade
- Sexual Dysfunction
- Support for Prosatate Cancer
- Survival prostate cancer
- Testosterone
- Theranostics
- Treatments for Prostate Cancer
- Tumor Spheres
- Uncategorized
- Vaccine
A prospective, randomized pilot study evaluating the effects of Metformin and lifestyle intervention on patients with prostate cancer.
This entry was posted in Hormonal Blockade, Journal Club, Prostate Cancer, Testosterone, Treatments for Prostate Cancer and tagged Glycemic Index, lifestyle, Metformin. Bookmark the permalink.
You must log in to post a comment.